Adjuvant Chemotherapy for Non-Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial uses a test that examines 14 genes to predict if early-stage lung cancer will return or spread after surgery. It targets patients with Stage I or Stage IIA non-small cell lung cancer who are at high risk. The test helps doctors decide if additional treatment like chemotherapy is needed.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators or your doctor for more information.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you have been on systemic chemotherapy or anti-cancer agents in the last 5 years, you may not be eligible to participate.
What safety data exists for adjuvant chemotherapy in non-small cell lung cancer?
Safety data for adjuvant chemotherapy in non-small cell lung cancer includes information on adverse effects, particularly in early-stage populations and long-term survivors, as well as treatment-related toxicity observed in the general population. Studies have evaluated the safety profile in older patients and the impact of delayed chemotherapy initiation on patient tolerance.12345
Is adjuvant chemotherapy generally safe for humans?
Adjuvant chemotherapy for non-small cell lung cancer has been studied for its safety, with some reports of unresolved adverse effects, especially in early-stage patients or long-term survivors. The safety profile has been evaluated in older patients, showing that while it can be beneficial, there are risks of treatment-related toxicity.12345
Is adjuvant chemotherapy a promising treatment for non-small cell lung cancer?
Yes, adjuvant chemotherapy is a promising treatment for non-small cell lung cancer. It has been shown to improve survival rates for patients who have had surgery to remove the cancer. Studies have found that it can increase the 5-year survival rates by 4% to 15%, making it a standard treatment option for these patients.678910
How is adjuvant chemotherapy for non-small cell lung cancer different from other treatments?
Adjuvant chemotherapy for non-small cell lung cancer (NSCLC) is unique because it is given after surgery to help prevent cancer from coming back, and it typically involves a combination of drugs like cisplatin and vinorelbine. This approach has been shown to improve survival rates by 4% to 15% in patients with completely resected NSCLC, making it a standard treatment option.678910
What data supports the idea that Adjuvant Chemotherapy for Non-Small Cell Lung Cancer is an effective treatment?
The available research shows that adjuvant chemotherapy, which is a treatment given after surgery, can improve survival rates for patients with non-small cell lung cancer. For example, one study found that this treatment increased 5-year survival rates by 4% to 15%. Another analysis showed a 5.4% increase in survival rates when using a specific drug combination. These studies suggest that adjuvant chemotherapy can help patients live longer after their cancer has been surgically removed.810111213
What data supports the effectiveness of the treatment Adjuvant Chemotherapy for Non-Small Cell Lung Cancer?
Research shows that adjuvant chemotherapy, especially with cisplatin-based drugs, can improve the 5-year survival rates of patients with non-small cell lung cancer by 4% to 15% after surgery. This treatment is particularly beneficial for patients with completely resected tumors, providing a survival advantage of about 5% at 5 years.810111213
Who Is on the Research Team?
David R Spigel, MD
Principal Investigator
Sarah Cannon, The Cancer Institute of HCA Healthcare
Are You a Good Fit for This Trial?
This trial is for adults who've had surgery to remove Stage I or IIA non-squamous NSCLC and are at high risk of the cancer returning. They must be able to undergo chemotherapy, have a life expectancy of over 5 years excluding their lung cancer diagnosis, and be in good physical condition with fully healed surgical incisions.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive adjuvant chemotherapy or undergo radiographic surveillance based on risk assessment
Follow-up
Participants are monitored for disease-free survival and overall survival
What Are the Treatments Tested in This Trial?
Interventions
- Adjuvant Chemotherapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Razor Genomics
Lead Sponsor
Encore Clinical
Collaborator